Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform, Questions About Near-Term Growth
October 9, 2012 7:13 AM EDT(Updated - October 9, 2012 8:19 AM EDT)
Oppenheimer downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Outperform to Perform.
The firm comments: "On 10/8, OPTR hosted an analyst day highlighting the performance of DIFICID since launch, and more specifically during 3Q12. OPTR also presented reasoning behind... More
